

1.3.3.3 Excretions	20
1.3.3.4 Metabolism	20
1.3.4 Propranolol toxicity	23
1.3.5 Propranolol adverse effects	23
1.3.6 Propranolol contraindications	23
1.3.7 Propranolol drug interactions	24
1.3.7.1 Propranolol Pharmacokinetic interactions	24
1.3.7.1 Propranolol pharmacodynamic interactions	24
1.4 Glucosamine (GlcN)	25
1.4.1 Glucosamine in the treatment of osteoarthritis	26
1.4.2 Other Glucosamine effects	26
1.4.3 Glucosamine Pharmacokinetics	27
1.4.3.1 Orally administered GlcN	27
1.4.3.2 Intravenously administered GlcN	27
1.4.4 Biochemical pathways	28
1.4.4.1 Hexosamine biosynthetic pathway	29
1.4.5 Glucosamine safety and toxicity	31
1.4.5.1 Orally administered GlcN	31
1.4.5.2 Intravenously administered GlcN	31
1.4.5.3 Glucosamine safety on human	31
1.5 Cimetidine	33
1.5.1 Cimetidine drug interactions	33
1.6 Rifampin (Rifampicin)	34
1.6.1 Rifampin drug interactions	34
1.7 Bioanalytical HPLC method validation parameters definitions (EMEA)	35
1.7.1 Accuracy	35
1.7.2 Precision	36
1.7.3 Linearity	37
1.7.4 Stability	37